Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has shared an announcement.
NetraMark Holdings has signed a contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial for a new psychiatric medicine. This collaboration highlights the increasing recognition of NetraMark’s AI technology in enhancing clinical trial success by identifying patient subpopulations and optimizing study outcomes. The agreement further extends NetraMark’s portfolio in neuroscience, oncology, and complex pain, demonstrating its capacity to deliver precision-trial insights that support drug development.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions for the pharmaceutical industry. The company offers a unique topology-based algorithm that segments patient data into subsets, enabling the use of various ML methods to transform data into intelligent insights. This allows NetraMark to work with smaller datasets and accurately classify patients for drug sensitivity and treatment efficacy.
YTD Price Performance: 19.61%
Average Trading Volume: 50,419
Technical Sentiment Signal: Buy
Current Market Cap: C$104.7M
For an in-depth examination of AIAI stock, go to TipRanks’ Overview page.